Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:41 PM
Ignite Modification Date:
2025-12-24 @ 1:41 PM
NCT ID:
NCT06172595
Eligibility Criteria:
Inclusion Criteria:
* Men or Women, aged 21 years or older at time of screening
* Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
* With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
* Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
* Subject must consent to undergo all study procedures
Exclusion Criteria:
* Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
* Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
* Proven cerebral metastases
* IDH-mutated gliomas
* Pregnancy/ breast-feeding
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Study:
NCT06172595
Study Brief:
Protocol Section:
NCT06172595